The 10 US Biosimilar Launches That Could Drive Big Savings By 2027
Biosimilar versions of drugs like Humira, Stelara and Eylea are among the products that could generate cumulative sales of $129bn over the next five years, according to IQVIA.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: 10 big upcoming US biosimilar launches; Kisqali strikes gold in early adjuvant breast cancer; Zolgensma shows the promise and limitations of gene therapy; Chinese biotechs advancing multiple ADCs; and Scrip Asks about diversity, equity and inclusion in pharma.
‘Inertia’ Likely To Restrain Biosimilar Humira In US Market, Experts Say
PBM contracting and payer formulary placement for branded Humira signal headwinds for biosimilar versions in the US, according to participants in an IQVIA-sponsored panel.
Roche Clinical Lead Labels Lucentis Biosimilars ‘Pandora’s Box’
Eight months after biosimilar competition to Roche’s Lucentis (ranibizumab) emerged in the US, ophthalmologists and doctors remain confused about how to incorporate them into their practice, a clinical trial lead representing the Swiss originator has proffered.